{"publication_id":"40ee40b9-6c56-499a-8ac8-120a3efd2edf","content_hash":"sha256:eaacf93a88c861870ece2f4f18a813b0d401a6c26dbc5ce7d748184278d1f9f3","nodes":[{"id":"40ee40b9-6c56-499a-8ac8-120a3efd2edf","type":"publication","title":"Sex-specific adipose tissue macrophage activation as a predictive biomarker for rapamycin's lifespan outcomes"},{"id":"claim_1","type":"claim","text":"The cited A/B receipts support a specific working claim: rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females; rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females and males, respectively. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"`fact_id=135475` (`A_core`) — rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females doi=10.1093/gerona/glz177"},{"id":"claim_4","type":"claim","text":"`fact_id=135476` (`A_core`) — rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females and males, respectively doi=10.1093/gerona/glz177"},{"id":"claim_5","type":"claim","text":"`fact_id=135477` (`A_core`) — rapamycin led to a 56% increase of CD45+ leukocytes in gWAT, where the majority of these are ATMs doi=10.1093/gerona/glz177"},{"id":"claim_6","type":"claim","text":"`fact_id=166319` (`A_core`) — Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit. doi=10.1111/acel.12496"},{"id":"claim_7","type":"claim","text":"_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._"},{"id":"source_1","type":"source","study":"Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging","year":2019,"doi":"10.1093/gerona/glz177","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice","year":2016,"doi":"10.7554/eLife.16351","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","year":2009,"doi":"10.1038/nature08221","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction","year":2014,"doi":"10.1111/acel.12194","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer","year":2016,"doi":"10.1111/acel.12496","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"40ee40b9-6c56-499a-8ac8-120a3efd2edf","to":"claim_1","type":"contains_claim"},{"from":"40ee40b9-6c56-499a-8ac8-120a3efd2edf","to":"claim_2","type":"contains_claim"},{"from":"40ee40b9-6c56-499a-8ac8-120a3efd2edf","to":"claim_3","type":"contains_claim"},{"from":"40ee40b9-6c56-499a-8ac8-120a3efd2edf","to":"claim_4","type":"contains_claim"},{"from":"40ee40b9-6c56-499a-8ac8-120a3efd2edf","to":"claim_5","type":"contains_claim"},{"from":"40ee40b9-6c56-499a-8ac8-120a3efd2edf","to":"claim_6","type":"contains_claim"},{"from":"40ee40b9-6c56-499a-8ac8-120a3efd2edf","to":"claim_7","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}